Engineered immune cells aim to stop lymphoma relapse after transplant

NCT ID NCT02663297

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 11, 2026 · Last updated Jun 14, 2026 · Updated 1 time

Summary

This early-phase study tests a treatment that adds a special antibody to a patient's own immune cells (T cells) to help them find and attack lymphoma cells. The goal is to find a safe dose of these modified cells to give after a stem cell transplant, to try to prevent the cancer from returning. The study includes 18 adults and children with Hodgkin or non-Hodgkin lymphoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, 27599, United States
Wake Forest University

Winston-Salem, North Carolina, 27157, United States

Conditions

Explore the condition pages connected to this study.

HODGKIN DISEASE IMMUNE SYSTEM DISEASES IMMUNOPROLIFERATIVE DISORDERS LYMPHATIC DISEASES LYMPHOMA LYMPHOMA, NON-HODGKIN LYMPHOPROLIFERATIVE DISORDERS NEOPLASMS NEOPLASMS BY HISTOLOGIC TYPE

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

CD30+ LYMPHOMA